Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on May 11, 2021

Rhea-AI Summary

Myovant Sciences (NYSE: MYOV) will host a conference call on May 11, 2021, at 8:30 AM ET to discuss corporate updates and financial results for its fiscal year ending March 31, 2021. Investors can access the call via the investor relations page on Myovant's website. The company is focused on redefining care for women's and men's health and has products under regulatory review for various conditions, including advanced prostate cancer and uterine fibroids, which may significantly impact future revenue.

Positive

• Approval of ORGOVYX™ as the first oral GnRH receptor antagonist for advanced prostate cancer.
• Lead product candidate under regulatory review for uterine fibroids and completed Phase 3 studies for endometriosis.

Negative

• None.

BASEL, Switzerland, May 04, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its fourth fiscal quarter and fiscal year 2020, ended March 31, 2021. The webcast and conference call will be held at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on May 11, 2021.

Investors and the general public may access a live webcast of the call by visiting the investor relations page of Myovant’s website at investors.myovant.com. Institutional investors and analysts may also participate in the conference call by dialing 1-800-532-3746 in the U.S. or +1-470-495-9166 from outside the U.S.

A replay of the webcast, along with the earnings press release and presentation materials, will be archived on Myovant’s investor relations website.

About Myovant Sciences 
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. ORGOVYX™ (relugolix) was approved by the U.S. Food and Drug Administration in 2020 as the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and relugolix is also under regulatory review in Europe for men with advanced prostate cancer. Our lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in the U.S. and Europe for women with uterine fibroids, has completed Phase 3 registration-enabling studies for women with endometriosis, and is being assessed for contraceptive efficacy in healthy women ages 18-35 years who are at risk for pregnancy. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn.

Investor Contact:
Ryan Crowe
Vice President, Investor Relations
+1 (650) 781-9106
investors@myovant.com

Media Contact:
Albert Liao
Director, Corporate Communications
+1 (650) 410-3055
media@myovant.com

FAQ

When is Myovant Sciences' financial results conference call?

The conference call is scheduled for May 11, 2021, at 8:30 AM ET.

What is Myovant Sciences focusing on?

Myovant Sciences is focused on redefining care for women's and men's health.

What products does Myovant have under regulatory review?

Myovant has products under review for advanced prostate cancer and uterine fibroids.

What is ORGOVYX™?

ORGOVYX™ is the first oral GnRH receptor antagonist approved for advanced prostate cancer.

How can I access the conference call?

The conference call can be accessed via the investor relations page on Myovant's website.